Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00064077 · OUTCOME

Duration of Overall Survival (OS)

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix · Source last updated 2018-10-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)

What was measured

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.

Analysis population: Evaluable (treatment)

Groups in this outcome

Arm I (Paclitaxel, Cisplatin)

Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2. Cisplatin: Given IV Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies

Arm II (Vinorelbine, Cisplatin)

Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1. Cisplatin: Given IV Quality-of-Life Assessment: Ancillary studies Vinorelbine Tartrate: Given IV

Arm III (Gemcitabine, Cisplatin)

Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II. Cisplatin: Given IV Gemcitabine Hydrochloride Quality-of-Life Assessment: Ancillary studies

Arm IV (Topotecan, Cisplatin)

Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II. Cisplatin: Given IV Quality-of-Life Assessment: Ancillary studies Topotecan Hydrochloride: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Paclitaxel, Cisplatin)103
Arm II (Vinorelbine, Cisplatin)108
Arm III (Gemcitabine, Cisplatin)112
Arm IV (Topotecan, Cisplatin)111

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I (Paclitaxel, Cisplatin)12.87Not reported10.0216.76Not reported
Arm II (Vinorelbine, Cisplatin)9.99Not reported8.2512.25Not reported
Arm III (Gemcitabine, Cisplatin)10.28Not reported7.6211.60Not reported
Arm IV (Topotecan, Cisplatin)10.25Not reported8.6111.66Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        10.02
        upper Limit
        16.76
        value
        12.87
      2. group Id
        OG001
        lower Limit
        8.25
        upper Limit
        12.25
        value
        9.99
      3. group Id
        OG002
        lower Limit
        7.62
        upper Limit
        11.60
        value
        10.28
      4. group Id
        OG003
        lower Limit
        8.61
        upper Limit
        11.66
        value
        10.25
denoms
  1. counts
    1. group Id
      OG000
      value
      103
    2. group Id
      OG001
      value
      108
    3. group Id
      OG002
      value
      112
    4. group Id
      OG003
      value
      111
    units
    Participants
description
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2. Cisplatin: Given IV Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
    id
    OG000
    title
    Arm I (Paclitaxel, Cisplatin)
  2. description
    Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1. Cisplatin: Given IV Quality-of-Life Assessment: Ancillary studies Vinorelbine Tartrate: Given IV
    id
    OG001
    title
    Arm II (Vinorelbine, Cisplatin)
  3. description
    Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II. Cisplatin: Given IV Gemcitabine Hydrochloride Quality-of-Life Assessment: Ancillary studies
    id
    OG002
    title
    Arm III (Gemcitabine, Cisplatin)
  4. description
    Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II. Cisplatin: Given IV Quality-of-Life Assessment: Ancillary studies Topotecan Hydrochloride: Given IV
    id
    OG003
    title
    Arm IV (Topotecan, Cisplatin)
param Type
MEDIAN
population Description
Evaluable (treatment)
reporting Status
POSTED
time Frame
Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)
title
Duration of Overall Survival (OS)
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice